Genmab, GlaxoSmithKline deal

Genmab declined to exercise its option to co-promote Arzerra ofatumumab, Bexar tositumomab and Arranon/ Atriance nelarabine in exchange for a $4.5 million payment from GlaxoSmithKline that will be triggered by FDA's acceptance of the first BLA for Arzerra for an oncology indication. The companies expect to submit a BLA for the human antibody against CD20 to treat chronic lymphocytic leukemia (CLL) this month. ...